The Open UniversitySkip to content
 

Spleen tyrosine kinase (SYK) blocks autophagic Tau degradation in vitro and in vivo

Schweig, Jonas Elias; Yao, Hailan; Coppola, Kyle; Jin, Chao; Crawford, Fiona; Mullan, Michael and Paris, Daniel (2019). Spleen tyrosine kinase (SYK) blocks autophagic Tau degradation in vitro and in vivo. Journal of Biological Chemistry, 294(36) pp. 13378–13395.

Full text available as:
Full text not publicly available (Version of Record)
Due to publisher licensing restrictions, this file is not available for public download until 6 September 2020
DOI (Digital Object Identifier) Link: https://doi.org/10.1074/jbc.RA119.008033
Google Scholar: Look up in Google Scholar

Abstract

Spleen tyrosine kinase (SYK) plays a major role in inflammation and in adaptive immune responses and could therefore contribute to the neuroinflammation observed in various neurodegenerative diseases. Indeed, previously we have reported that SYK also regulates amyloid β (Aβ) production and hyperphosphorylation of Tau protein involved in these diseases. Moreover, SYK hyperactivation occurs in a subset of activated microglia, in dystrophic neurites surrounding Aβ deposits, and in neurons affected by Tau pathology both in individuals with Alzheimer’s disease (AD) and in AD mouse models. SYK activation increases Tau phosphorylation and accumulation, suggesting that SYK could be an attractive target for treating AD. However, the mechanism by which SYK affects Tau pathology is not clear. In this study, using cell biology and biochemical approaches, along with immuno -precipitation and -blotting, RT-qPCR, and ELISA assays, we found that SYK inhibition increases autophagic Tau degradation without impacting Tau production. Using neuronlike SH-SY5Y cells, we demonstrate that SYK acts upstream of the mTOR pathway and that pharmacological inhibition or knockdown of SYK decreases mTOR pathway activation and increases autophagic Tau degradation. Interestingly, chronic SYK inhibition in a tauopathy mouse model profoundly reduced Tau accumulation, neuroinflammation, neuronal and synaptic loss and also reversed defective autophagy. Our results further suggest that the SYK up-regulation observed in the brains of individuals with AD contributes to defective autophagic clearance leading to the accumulation of pathogenic Tau species. These findings further highlight SYK as a therapeutic target for the treatment of tauopathies and other neurodegenerative proteinopathies associated with defective autophagic clearance.

Item Type: Journal Item
Copyright Holders: 2019 American Society for Biochemistry and Molecular Biology Privacy Policy
ISSN: 0021-9258
Academic Unit/School: Faculty of Science, Technology, Engineering and Mathematics (STEM)
Item ID: 66800
Depositing User: ORO Import
Date Deposited: 18 Sep 2019 14:37
Last Modified: 04 Oct 2019 16:22
URI: http://oro.open.ac.uk/id/eprint/66800
Share this page:

Metrics

Altmetrics from Altmetric

Citations from Dimensions

Actions (login may be required)

Policies | Disclaimer

© The Open University   contact the OU